JAGX vs. PHIO, BCDA, PHXM, AIMD, CSCI, TRIB, GLYC, NKGN, KPRX, and BTAI
Should you be buying Jaguar Animal Health stock or one of its competitors? The main competitors of Jaguar Animal Health include Phio Pharmaceuticals (PHIO), BioCardia (BCDA), PHAXIAM Therapeutics (PHXM), Ainos (AIMD), COSCIENS Biopharma (CSCI), Trinity Biotech (TRIB), GlycoMimetics (GLYC), NKGen Biotech (NKGN), Kiora Pharmaceuticals (KPRX), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry.
Jaguar Animal Health vs. Its Competitors
Jaguar Animal Health (NASDAQ:JAGX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
In the previous week, Jaguar Animal Health had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 1 mentions for Jaguar Animal Health and 0 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.00 beat Jaguar Animal Health's score of -0.34 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.
Jaguar Animal Health currently has a consensus price target of $60.00, suggesting a potential upside of 2,239.18%. Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 475.18%. Given Jaguar Animal Health's higher probable upside, analysts plainly believe Jaguar Animal Health is more favorable than Phio Pharmaceuticals.
Phio Pharmaceuticals has lower revenue, but higher earnings than Jaguar Animal Health.
12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.4% of Jaguar Animal Health shares are held by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Phio Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -343.92%. Phio Pharmaceuticals' return on equity of -105.65% beat Jaguar Animal Health's return on equity.
Jaguar Animal Health has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Summary
Phio Pharmaceuticals beats Jaguar Animal Health on 7 of the 11 factors compared between the two stocks.
Get Jaguar Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JAGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:JAGX) was last updated on 7/5/2025 by MarketBeat.com Staff
